Our Approach

Translating the DARPin® difference into patient benefit.

At Molecular Partners we are focused singly on one task: translating the differentiating features of DARPin® proteins into patient benefit. We constantly challenge current approaches to come up with solutions to move the needle of medicine.

Possible Solution

Some targets, such as peptide-MHC complexes, carry high therapeutic promise, but have proven exceptionally challenging with conventional approaches.

DARPin® proteins bind their targets with a concave surface that might be ideally suited to engage with pMHC complexes with high affinity and specificity.

Example: pMHC-DARPin® candidates

Activating immune cells is a powerful way to fight cancer. Systemic activation of immune cells can however lead to dose-limiting side effects, providing no therapeutic window, as is often seen for agonistic immune cell targets.

Multi-DARPin® candidates can be engineered to activate immune cells preferentially in the tumor, thereby avoiding dose-limiting side effects and opening a new therapeutic window.

Example: MP0310 / FAPxCD40

Current approaches targeting Her-2 use either immune cells or deliver drugs to kill tumor cells, both of which can carry side effects.

Allosteric modulation of Her-2 can “handcuff” the protein and kill tumor cells without the need of the immune system or drug delivery.

Example: MP0274

Under treatment with standard therapies some tumors react by upregulating escape pathways, leading to adaptive resistance.

Multi-DARPin® approaches are ideally suited to block different escape pathways in parallel, with the potential to overcome resistance and reactivate standard of care therapies.

Example: MP0250